TICKERNERD
Menu
GENBHealthcare · Biotechnology

GENB Stock Forecast: Generate Biomedicines, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$14
+3.10% on the day

The 6 Wall Street analysts covering Generate Biomedicines, Inc. hold a median 12-month price target of $27 — +93.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.8B
Ticker Nerd rank
1 / 100
Median analyst target
$27
Analysts covering
6
Revenue$6.3M
Operating income−$71.6M
Net income−$67.3M
Free cash flow−$58.9M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.4%
1M
−12.0%
From high
−31.4%
From low
+24.8%
$11
$20
Range since 27 Feb 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

GENB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Generate Biomedicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
37
Size
37
Value
10
Momentum
8
Growth
8
Accruals
8
Issuance
4
Volatility
4
Quality
3

Revisions (37): Analysts have, on balance, been raising their forecasts.

Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GENB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GENB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 27 Feb 2026Adjusted close, US dollars
$10$15$20$25$30Apr 26Jul 26Oct 26GENBHigh $30Median $27Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $22Median $27High $30

The green dot is the last close — the median target sits +93.0% from it.

Recent analyst actionsNewest first

Of the 14 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
5 Oct 2026HC Wainwright & Co.ReiteratesBuy$30
8 Sept 2026HC Wainwright & Co.ReiteratesBuy$30
28 Aug 2026HC Wainwright & Co.MaintainsBuy$25 → $30
28 Aug 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026Morgan StanleyMaintainsOverweight—
14 May 2026Morgan StanleyMaintainsOverweight$20 → $22
8 May 2026HC Wainwright & Co.MaintainsBuy$16 → $25
8 May 2026HC Wainwright & Co.MaintainsBuy—
13 Apr 2026HC Wainwright & Co.InitiatesBuy—
24 Mar 2026Cantor FitzgeraldInitiatesOverweight—
24 Mar 2026Goldman SachsInitiatesBuy—
24 Mar 2026GuggenheimInitiatesBuy—
24 Mar 2026Morgan StanleyInitiatesOverweight—
24 Mar 2026Piper SandlerInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GENB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GENB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

GENB vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Apr 26Jul 26Oct 26GENBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GENB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Generate Biomedicines, Inc. (GENB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.4×

Cheaper than 91% of US stocks

Price / sales
65.6×

Cheaper than 5% of US stocks

Price / book
3.8×

Cheaper than 26% of US stocks

EV / EBITDA
−5.5×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
−37.7%

Higher than 7% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1134.2%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
40.0%

Higher than 91% of US stocks

Return on assets
−75.6%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Generate Biomedicines, Inc. (GENB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Generate Biomedicines, Inc. has a market value of $1.8B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $32.5M. The latest quarter shrank 37.7% year on year.

  • Net income over the same four quarters: −$230.0M, a −708.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.74.

  • Free cash flow in the twelve months to 30 June 2026: −$245.9M.

  • Shares outstanding: 128.3M.

  • Trailing P/E: −6.4×; forward P/E: −5.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Generate Biomedicines, Inc. employs 312 people — $104K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

GENB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GENBGenerate Biomedicines, Inc.$1.8B
1
URGNUroGen Pharma Ltd.$1.8B
83
NTLAIntellia Therapeutics, Inc.$1.8B
53
ZYMEZymeworks, Inc.$1.8B
63
NVAXNovavax, Inc.$1.8B
58
TRVITrevi Therapeutics, Inc.$1.8B
48
XNCRXencor, Inc.$1.8B
83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Generate Biomedicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GENB news & analysis

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer

GlobeNewsWire · 1 Oct 2026positive

Roswell Park Comprehensive Cancer Center and Generate Biomedicines launched an exclusive clinical trial of GB-5267, an AI-engineered "armored" CAR T cell therapy for ovarian cancer, with the first patient treated. The therapy targets MUC16, a biomarker over-expressed in over 80% of ovarian tumors, and is designed to avoid pre-infusion chemotherapy and its side effects.

Why it matters — This marks the first next-generation cell therapy for ovarian cancer to enter clinical trials, representing a key clinical milestone for Generate Biomedicines' AI-driven cell therapy pipeline.

Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

Generate Biomedicines, Inc. (GENB) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation made available via Seeking Alpha. The event provided a forum for the company's management to discuss its business with investors.

Why it matters — The conference appearance gives GENB watchers access to management commentary on the company's pipeline and strategy from a major healthcare investment event.

Generate Biomedicines Inc. to Participate in September Investor Conferences

GlobeNewsWire · 8 Sept 2026neutral

Generate Biomedicines Inc. (Nasdaq: GENB) announced that members of its management team will participate in presentations at upcoming investor conferences in September 2026. The company did not specify dates or which conferences are included.

Why it matters — GENB watchers may gain insight into the company's strategy and updates through its management team's presentations at these investor conferences.

Generate Biomedicines stock jumps as post-IPO lock-up set to expire

Proactive Investors · 25 Aug 2026neutral

Shares of Generate Biomedicines rose more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period on Wednesday. The expiration will free company insiders, early investors and major shareholders to sell shares issued in the company's $400 million IPO, which included 25 million shares.

Why it matters — GENB watchers will be tracking the end of the lock-up, which permits insider and early-investor share sales and could affect the stock's trading dynamics.

Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 6 Aug 2026positive

Generate Biomedicines reported its second quarter 2026 financial results, holding approximately $457.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026. The business update noted Phase 3 recruitment for GB-0895 across six global regions, planned presentation of Phase 1b GB-0895 COPD data at the ERS Congress 2026, full enrollment in the first cohort of the Phase 1 GB-4362 study, and platform advancements across strategic collaborations.

Why it matters — GENB watchers would care because the update shows clinical trial advancement across multiple programs alongside a reported cash position supporting the company's pipeline.

FAQ

Frequently asked questions about GENB stock

What is the GENB stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Generate Biomedicines, Inc. have a median 12-month price target of $27, with estimates ranging from $22 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GENB stock a buy right now?

Of the 6 analysts covering Generate Biomedicines, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Generate Biomedicines, Inc. 1 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GENB?

As at 8 Oct 2026, Generate Biomedicines, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (37 of 100).

Will GENB stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +93.0% from the last close, and Ticker Nerd's factor model ranks Generate Biomedicines, Inc. 1 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GENB stock forecast for 2030?

No analyst covering Generate Biomedicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GENB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $30 over the next 12 months.

What does Generate Biomedicines, Inc. do?

Generate Biomedicines, Inc. is a clinical-stage biotechnology company focused on using machine learning and generative biology to design novel protein therapeutics.

What is the latest news on GENB?

The most recent item we track (GlobeNewsWire, 1 Oct 2026): "Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer". Roswell Park Comprehensive Cancer Center and Generate Biomedicines launched an exclusive clinical trial of GB-5267, an AI-engineered "armored" CAR T cell therapy for ovarian cancer, with the first patient treated. The therapy targets MUC16, a biomarker over-expressed in over 80% of ovarian tumors, and is designed to avoid pre-infusion chemotherapy and its side effects.

Company

About Generate Biomedicines, Inc.

Generate Biomedicines, Inc. is a clinical-stage biotechnology company focused on using machine learning and generative biology to design novel protein therapeutics. The company’s Generate Platform combines computational design with biological engineering to create medicines across multiple protein-based modalities, including antibodies, enzymes, cytokines, peptides, and cell therapies. Its pipeline includes investigational programs such as GB-0895 for severe asthma, GB-4362, and GB-5267, reflecting its emphasis on developing treatments for complex and hard-to-address diseases. Based in Somerville, Massachusetts, Generate Biomedicines operates at the intersection of artificial intelligence, drug discovery, and therapeutic development, serving as a platform-driven innovator in modern biomedicine.

CEO Mr. Michael T. Nally M.B.A. · 312 employees · United States · https://generatebiomedicines.com